免疫治疗相关乳腺反应性毛细血管增生症1例

A case report of immunotherapy-related breast reactive capillary endothelial proliferation

反应性毛细血管增生症(reactive capillary endothelial proliferation,RCEP)是卡瑞利珠单抗治疗过程中最常见的免疫相关不良反应(immune-related adverse event,irAE)。在接受卡瑞利珠单抗单药治疗的晚期实体肿瘤患者中,大部分的患者会出现RCEP。临床上irAE主要发生在皮肤,而出现在乳腺的RCEP则非常罕见。本文报道了1例女性肺腺癌患者,在接受卡瑞利珠治疗后,出现了乳腺RCEP,未进行停药后自行消退。本文结合相关文献对其发生的机制及可能存在的临床意义进行了分析,旨在为临床实践提供参考策略。

Reactive capillary endothelial proliferation(RCEP)is the most common immune-related adverse event(irAE)during Camrelizumab treatment.RCEP occurs in the majority of patients with advanced solid tumors who receive Camrelizumab monotherapy.This irAE mainly occurs in the skin clinically,and RCEP in the breast is quite rare.Here we report a case of a female patient with lung adenocarcinoma who developed breast RCEP a?ter Camrelizumab treatment and regressed spontaneously without drug withdrawal.We analyze the mechanism of its occurrence and its possible clinical significance based on relevant literature,aiming to provide guidance for clinical practice.